Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IKT 
Inhibikase Therapeutics Inc (IKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 81.94% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 127.12M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 2 | Beta 0.91 | 52 Weeks Range 1.12 - 4.20 | Updated Date 08/15/2025 |
52 Weeks Range 1.12 - 4.20 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.95% | Return on Equity (TTM) -79.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 34018514 | Price to Sales(TTM) 1000000 |
Enterprise Value 34018514 | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 2.75 | Enterprise Value to EBITDA 0.34 | Shares Outstanding 74341504 | Shares Floating 24869475 |
Shares Outstanding 74341504 | Shares Floating 24869475 | ||
Percent Insiders 13.02 | Percent Institutions 79.6 |
Upturn AI SWOT
Inhibikase Therapeutics Inc
Company Overview
History and Background
Inhibikase Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for Parkinson's disease and other related disorders. Founded in 2007, the company has focused on developing novel therapies based on its protein kinase inhibitor platform.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Developing small molecule kinase inhibitors to treat neurodegenerative diseases like Parkinson's disease.
Leadership and Structure
Dr. Milton Werner serves as the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Risuteganib (IC-268): A small molecule protein kinase inhibitor being developed for Parkinson's disease and related disorders. Currently in clinical trials. Market share is currently 0% as it is pre-revenue. Competitors include pharmaceutical companies developing treatments for Parkinson's such as Biogen (BIIB) and AbbVie (ABBV).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and a competitive landscape with both large pharmaceutical companies and smaller biotech firms. Demand for treatments for neurodegenerative diseases is growing due to an aging population.
Positioning
Inhibikase Therapeutics is a smaller biotech company focused on a specific niche within the neurodegenerative disease market. Its competitive advantage lies in its novel kinase inhibitor platform.
Total Addressable Market (TAM)
The global Parkinson's disease market is estimated at billions of dollars annually, with growth expected. Inhibikase aims to capture a portion of this market with its novel therapeutics. The 2023 TAM was estimated at $5.4 billion USD and projected to $7.5 billion USD in 2032. Inhibikase is positioned to enter the market if the drug receives final approval by the FDA.
Upturn SWOT Analysis
Strengths
- Novel kinase inhibitor platform
- Focus on underserved neurodegenerative disease market
- Experienced leadership team
- Proprietary technology
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- High risk associated with clinical trials
- Dependence on single drug candidate currently
- Relatively small company size
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to other neurodegenerative diseases
- Positive clinical trial results
- Breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- ABBV
- TEVA
- SNY
Competitive Landscape
Inhibikase faces competition from larger pharmaceutical companies with established pipelines and resources. Its success hinges on demonstrating the efficacy and safety of its novel kinase inhibitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by research and development milestones and financing activities.
Future Projections: Future growth is dependent on the successful completion of clinical trials and the potential commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include progressing clinical trials for Parkinson's disease treatment and exploring partnerships.
Summary
Inhibikase Therapeutics is a high-risk, high-reward biotechnology company. The company is pre-revenue, and its future depends on clinical trial success. While the proprietary inhibitor technology shows promise, the company faces significant competition. Investors should be aware of the inherent risks associated with early-stage biotech companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Inhibikase Therapeutics Inc
Exchange NASDAQ | Headquaters Atlanta, GA, United States | ||
IPO Launch date 2020-12-23 | CEO & Director Mr. Mark T. Iwicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.inhibikase.com |
Full time employees 15 | Website https://www.inhibikase.com | ||
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.